Sagimet Biosciences Inc.
SGMT · XNASCIK 1400118fmd_1BMFX5Z4N86DYKE5PT28192D3HManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2022 to Sep 30, 2026, 19 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total revenues | – | 2 | – | – |
| Research and development | 25 | 20 | 38 | 39 |
| Total operating expenses | 31 | 33 | 54 | 57 |
| Operating income | (31) | (31) | (54) | (57) |
| Interest and investment income | 1 | 3 | 9 | 6 |
| Other non-operating income (expense) | 1 | 3 | 9 | 6 |
| Income tax expense | – | – | 0 | 0 |
| Net income | (30) | (28) | (46) | (51) |